Introduction
============

Negative intrathoracic pressure produced by spontaneous breathing is an important driving force for pulmonary blood flow in the Fontan circulation, which is characterized by the lack of the pulmonary ventricle. Therefore, positive-pressure ventilation, including continuous positive airway pressure (CPAP) via the nasal cannula, and conventional mechanical ventilation are thought to be detrimental for the Fontan circulation, because they impede venous return and increase central venous pressure (CVP).

High-flow nasal cannula (HFNC) therapy is a relatively new mode of noninvasive ventilation that is as effective as and better tolerated than CPAP ventilation.[@b1-cmc-9-2015-109] More importantly, in contrast to CPAP ventilation, HFNC supports respiratory effort with a minimal elevation in airway pressure and, consequently, minimal elevation in intrathoracic pressure.[@b1-cmc-9-2015-109] This feature of HFNC may be of particular benefit for respiratory support in Fontan patients, in whom positive airway pressure exerts deleterious effects on hemodynamic events. In this case report, we present detailed data regarding the effects of HFNC therapy on Fontan hemodynamics. The patient's guardian gave written consent for the publication of this report.

Clinical Summary
================

The patient was a 10-year-old girl (body weight, 34 kg) with tricuspid stenosis and regurgitation, atrial and ventricular septum defect, and patent ductus arteriosus. She underwent pulmonary artery banding at one month of age and subsequent bidirectional Glenn anastomosis at the age of seven months. Thereafter, she underwent Fontan operation at the age of two years. Hemodynamic changes were evaluated before and five minutes after HFNC therapy during follow-up catheterization. Written informed consent for all the procedures during catheterization was obtained from the parents of the patient. HFNC was applied using heated and humidified gas at the flow rate of 30 L/minute with a fraction of inspired oxygen of 0.21 and 0.3. As summarized in [Table 1](#t1-cmc-9-2015-109){ref-type="table"}, after induction of HFNC, arterial oxygen saturation increased from 95% to 97% without a change in CVP. A reduction in the heart rate and pulmonary arterial and systemic arterial resistance, with an increase in cardiac output, was also observed. Thirty percent oxygen inhalation further amplified these favorable hemodynamic changes. Changes in the cerebral oxygenation status measured by near-infrared spectroscopy are shown in [Figure 1](#f1-cmc-9-2015-109){ref-type="fig"}. The tissue oxygenation index and oxygenated hemoglobin level increased after HFNC therapy, indicating improved oxygenation of the brain tissue. In addition, the deoxygenated hemoglobin level decreased, but the normalized tissue hemoglobin index did not alter, indicating an improved cerebral blood flow without congestion.

Discussion
==========

Several recent studies have reported that HFNC therapy improves oxygenation and provides dyspnea relief and comfort in patients with hypoxemia caused by various conditions.[@b2-cmc-9-2015-109] However, little information is available regarding the hemodynamic effects of HFNC. HFNC supports respiration through direct delivery of gas at high flow rates into the nasopharynx to create a reservoir of fresh gas and to reduce dead space, rather than through an increase in the end-expiratory pressure to increase lung volumes, and therefore, its effect on CVP should be minimum.[@b1-cmc-9-2015-109] Both pressure and volume requirements to support gas exchange were lower in HFNC than in conventional mechanical ventilation. In addition, HFNC may be a useful clinical adjunct to respiratory management and may cause minimal damage to Fontan circulation. In our Fontan patient, HFNC at 30 L/minute indeed improved oxygenation without an increase in CVP. It also reduced the heart rate, systemic vascular resistance, and pulmonary vascular resistance and increased the cardiac output. In addition, HFNC improved cerebral circulation, measured by near-infrared spectroscopy.

In the management immediately after the Fontan surgery, early establishment of spontaneous breathing is thought to be beneficial for the enhancement of hemodynamic performance of Fontan circulation through the generation of a negative intrathoracic pressure with inspiration.[@b3-cmc-9-2015-109] However, in clinical practice, not all patients can achieve extubation immediately after the surgery; furthermore, a rather unstable respiratory condition caused by early extubation exerts untoward effects on the Fontan circulation. As observed in the case of our patient, because HFNC could support respiration with a minimum increase in CVP, it may contribute to the establishment of favorable Fontan circulation immediately after the operation through early extubation. Similarly, HFNC therapy may play a role in the prevention of intubation in Fontan patients who show respiratory failure caused by unexpected events, such as respiratory infection and pleural effusion. Minimum effects of HFNC on CVP may also be beneficial for Fontan cerebral circulation ([Fig. 1](#f1-cmc-9-2015-109){ref-type="fig"}), because increased CVP in Fontan patients appears to confer increased outflow resistance to the cerebral circulation and thereby impairs cerebral perfusion, as previously reported by Kurishima et al.[@b4-cmc-9-2015-109] and Saiki et al.[@b5-cmc-9-2015-109] In addition, increased cardiac output with a reduction in the heart rate, systemic vascular resistance, and pulmonary vascular resistance strongly suggests that HFNC suppresses sympathetic nerve activity, probably through the secondary effects of improved oxygenation.

Other potential advantages of HFNC over other ventilatory modalities are summarized in [Table 2](#t2-cmc-9-2015-109){ref-type="table"}. HFNC can be safely and easily applied to individuals belonging to various age groups, ranging from newborns to adults. As compared to CPAP, HFNC rarely causes abdominal distension. In children, sedation may be needed during the application of CPAP and mechanical ventilation, but not during the application of HFNC. During HFNC, patients are able to speak, eat, and receive medications. Nonetheless, several potential disadvantages of HFNC therapy should be acknowledged. HFNC therapy may not be effective in patients with postoperative diaphragmatic paralysis. In the case of patients who show poor response to HFNC, positive-pressure ventilation should be used without any delay in intubation. HFNC allows delivery of up to 60 L/minute of heated and humidified gas; the optimal flow rate needs to be adjusted in a patient-specific manner. Higher flow rates are more effective in improving the oxygenation. In contrast, higher flow rates can cause discomfort to patients and may affect the intrathoracic pressure. Therefore, the optimal flow rate should be adjusted by balancing the abovementioned factors.

In conclusion, HFNC may be potentially useful, noninvasive ventilation, particularly for patients with Fontan circulation. Further studies in a large number of patients are warranted.
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![Changes in the cerebral oxygenation measured by near-infrared spectroscopy.\
**Abbreviations:** NHF, nasal high flow; TOI, total oxygen index; nTHI, normalized tissue hemoglobin index; ΔO~2~Hb, amount of oxygenated hemoglobin change; ΔHHb, amount of deoxygenated hemoglobin change.](cmc-9-2015-109f1){#f1-cmc-9-2015-109}

###### 

Hemodynamic changes before and after HFNC therapy.

                       BEFORE HFNC   AFTER HFNC (FIO~2~ AT 21%)   AFTER HFNC (FIO~2~ AT 30%)
  -------------------- ------------- ---------------------------- ----------------------------
  SaO~2~ (%)           95            97                           99
  SvO~2~ (%)           72            83                           86
  Heart rate (bpm)     85            75                           70
  AoP (mmHg)           146/90        145/87                       138/82
  CVP (mmHg)           11            11                           11
  Cardiac index        2.93          4.54                         4.85
  PVR (units × m^2^)   1.71          1.32                         1.03
  SVR (units × m^2^)   32.2          22.0                         19.2

**Abbreviations:** HFNC, high-flow nasal cannula; FiO~2~, fraction of oxygen; SaO~2~, arterial oxygen saturation; SvO~2~, mixed venous oxygen saturation; AoP, aortic pressure; CVP, central venous pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.

###### 

Comparison of HFNC with other modalities for ventilatory support.

                       NON-INVASIVE   INVASIVE                             
  -------------------- -------------- ---------- ------------ ------------ ------------
  Max FiO~2~           1.0            0.5--0.6   1.0          0.5--0.6     1.0
  Ventilation effect   DV↓            --         TV↑          TV↑          TV↑
  ITP                  → \~ ↑         →          ↑            → \~ ↓       ↑
  Application          Easy           Easy       Easy         Not easy     Not easy
  Oral intake          Possible       Possible   Impossible   Impossible   Impossible
  Discomfort           --             --         \+           ++           +++

**Abbreviations:** HFNC, high-flow nasal cannula; FM, face mask; CPAP, continuous positive airway pressure; NEEP, negative extrathoracic end-expiratory pressure; CMV, conventional mechanical ventilation; Max FiO~2~, maximum possible fraction of oxygen; ITP, intrathoracic pressure; DV, dead-space volume; TV, tidal volume.
